Early ART or PrEP? A Comparative Analysis of Effectiveness and Cost of HIV Prevention through Antiretroviral Drugs
Worldwide, we have more than 33 million people living with HIV (human immunodeficiency virus). It remains a challenge to find the best prevention methods. Keng’s research compares two new biomedical prevention methods that have used ART (antiretroviral therapy) to prevent HIV transmission in discordant couples (one member is infected but the other is not). One method is PrEP (pre-exposure prophylaxis), where the uninfected person takes antiretroviral drugs, and the other method begins ART in the infected member earlier than is clinically recommended to prevent transmission. The clinical trials data from both methods are published and available for analysis. Keng will use meta-analysis and cost-effectiveness analysis to compare and contrast both prevention strategies for a cohort of heterosexual couples living in southern Africa.
- Major: Public Health
- Mentor: Professor George Rutherford